SCYNEXIS, Inc.
(NASDAQ : SCYX)

( )
SCYX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
0.16%18.421.8%$132.46m
ICPTIntercept Pharmaceuticals, Inc.
4.05%90.5318.6%$94.99m
SAGESAGE Therapeutics, Inc.
0.89%166.988.8%$82.15m
JAZZJazz Pharmaceuticals Plc
3.03%129.782.3%$71.68m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.21%165.566.3%$60.71m
PRGOPerrigo Co. Plc
0.38%49.756.8%$54.82m
ZGNXZogenix, Inc.
0.48%37.399.9%$45.65m
UTHRUnited Therapeutics Corporation
5.53%104.3114.3%$44.47m
CTLTCatalent Inc
0.91%44.442.4%$39.76m
HZNPHorizon Pharma plc
2.98%25.266.7%$35.55m
PTLAPortola Pharmaceuticals, Inc.
2.76%35.407.6%$33.06m
ICLRICON Plc
3.89%135.054.1%$30.66m
ZYNEZynerba Pharmaceuticals Inc
4.21%9.908.3%$28.70m
MYOKMyoKardia, Inc.
2.06%49.072.4%$25.77m
MNKMallinckrodt Plc
3.15%18.3621.0%$25.24m

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.